1. Home
  2. RARE vs AVA Comparison

RARE vs AVA Comparison

Compare RARE & AVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RARE
  • AVA
  • Stock Information
  • Founded
  • RARE 2010
  • AVA 1889
  • Country
  • RARE United States
  • AVA United States
  • Employees
  • RARE N/A
  • AVA N/A
  • Industry
  • RARE Biotechnology: Pharmaceutical Preparations
  • AVA Power Generation
  • Sector
  • RARE Health Care
  • AVA Utilities
  • Exchange
  • RARE Nasdaq
  • AVA Nasdaq
  • Market Cap
  • RARE 3.5B
  • AVA 3.1B
  • IPO Year
  • RARE 2014
  • AVA N/A
  • Fundamental
  • Price
  • RARE $36.68
  • AVA $37.94
  • Analyst Decision
  • RARE Strong Buy
  • AVA Sell
  • Analyst Count
  • RARE 15
  • AVA 2
  • Target Price
  • RARE $90.53
  • AVA $38.00
  • AVG Volume (30 Days)
  • RARE 1.1M
  • AVA 649.9K
  • Earning Date
  • RARE 07-31-2025
  • AVA 08-06-2025
  • Dividend Yield
  • RARE N/A
  • AVA 5.21%
  • EPS Growth
  • RARE N/A
  • AVA N/A
  • EPS
  • RARE N/A
  • AVA 2.37
  • Revenue
  • RARE $590,689,000.00
  • AVA $1,946,000,000.00
  • Revenue This Year
  • RARE $18.94
  • AVA N/A
  • Revenue Next Year
  • RARE $28.93
  • AVA $3.94
  • P/E Ratio
  • RARE N/A
  • AVA $15.88
  • Revenue Growth
  • RARE 33.46
  • AVA 3.16
  • 52 Week Low
  • RARE $29.59
  • AVA $33.45
  • 52 Week High
  • RARE $60.37
  • AVA $43.09
  • Technical
  • Relative Strength Index (RSI)
  • RARE 51.86
  • AVA 45.45
  • Support Level
  • RARE $36.03
  • AVA $37.43
  • Resistance Level
  • RARE $37.74
  • AVA $38.27
  • Average True Range (ATR)
  • RARE 1.46
  • AVA 0.53
  • MACD
  • RARE -0.01
  • AVA 0.12
  • Stochastic Oscillator
  • RARE 26.56
  • AVA 67.88

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

About AVA Avista Corporation

Avista Corp is an electric and natural gas utility company. The company has two business segments including Avista Utilities, which provides electric distribution and transmission, and natural gas distribution services in parts of eastern Washington and northern Idaho, and also provides natural gas distribution service in parts of northeastern and southwestern Oregon. Avista Utilities has electric generating facilities in Washington, Idaho, Oregon, and Montana. AEL&P is a regulated utility providing electric services in Juneau, Alaska that is a wholly-owned subsidiary and the primary operating subsidiary of AERC.

Share on Social Networks: